Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences closes $450 million 9.5% notes and $1.65 billion credit refinancing

Neutral Impact 4 of 5 financing

Integra LifeSciences entered a $1.65 billion amended and restated credit agreement and closed a $450 million private offering of 9.500% senior secured notes due 2033, both on October 19, 2026. The company used the proceeds and new borrowings to repay in full its Existing Credit Agreement, which had a $1.3 billion revolver and a $775 million term loan. The filing shows new debt and higher-cost secured borrowing terms, but it does not report earnings or guidance changes.

Key points

  • Notes: $450 million principal, 9.500% interest, payable semi-annually, maturing November 1, 2033
  • Credit agreement: $600 million revolver and $600 million term loan A (five-year), plus $450 million term loan B (seven-year)
  • Term Loan B applicable rate is 4.25%; revolver and term loan A initially 3.00%, adjusting to 2.00% to 3.25% after the December 31, 2026 quarter
  • Existing $1.3 billion revolver and $775 million term loan were repaid in full with no early termination penalties

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECOct 19, 2026, 4:20 PM ET
Accession number0001193125-26-425271

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.